vTv Therapeutics (VTVT) Misses Q2 EPS by 15c

vTv Therapeutics (NASDAQ: VTVT) reported Q2 EPS of ($1.05), $0.15 worse than the analyst estimate of ($0.90).

For earnings history and earnings-related data on vTv Therapeutics (VTVT) click here.

You May Also Be Interested In

• Apple announced foldable iPhone Duo, starting at $1,999
• Dunkin' Boss Named Interim CEO of Inspire Brands Ahead of IPO - WSJ
• Oppenheimer Reiterates Outperform Rating on Compass Pathways (CMPS)